NCT00757029View on ClinicalTrials.gov

Pharmacogenetic Study of Methylphenidate in Attention Deficit/Hyperactivity Disorder(ADHD)

PHASE4CompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

August 31, 2008

Study Completion Date

August 31, 2010

Conditions
Attention Deficit Disorder With HyperactivityMethylphenidatePharmacogenetics
Interventions
GENETIC

norepinephrine transporter polymorphism,

OROS methylphenidate (Concerta) monopharmacotherapy dose : 18-54mg duration : 8 weeks genotyping : norepinephrine transporter (SLC6A2) polymorphism

Trial Locations (1)

Unknown

Hallym University Sacred Heart Hospital, Anyang-si

All Listed Sponsors
lead

Hallym University Medical Center

OTHER

NCT00757029 - Pharmacogenetic Study of Methylphenidate in Attention Deficit/Hyperactivity Disorder(ADHD) | Biotech Hunter | Biotech Hunter